Lindus Health Limited

Lindus Health Limited is a United Kingdom-based clinical research and drug development company headquartered in London. Originally founded as a technology-first clinical research organisation (CRO), the company has since repositioned itself around in-licensing, co-developing and acquiring drug assets and advancing them using its own integrated clinical trial delivery capability. It markets itself under the name Lindus Therapeutics, describing its mission as "next-generation drug development." The company's model combines a technology-enabled trial platform with asset development. Lindus states that it runs faster, higher-quality clinical trials by using technology to automate manual processes, recruit patients directly and provide real-time access to data. On the asset side, it in-licenses Phase I–III ready assets, focusing on non-ultrarare chronic disease aligned with its core therapeutic areas and proven execution capabilities. It identifies candidate assets using proprietary data and AI models, develops them internally, and then assesses acquisition, partnering, later-stage development or commercialisation as the path forward. Lindus reports $80 million in total funding, a team of 80 people across the United States and Europe, and more than 45 completed Phase I–IV trials across broad therapeutic areas. It also states that 82% of its trials completed enrollment on or ahead of timeline, measured against all 28 trials that completed enrollment within the past three years where Lindus was responsible for enrollment. Its trial execution spans the US, UK and Europe, with integrated Asia-Pacific partnerships. For its asset development strategy, Lindus says it is targeting deal close on initial assets through 2026, with first trials launching in the first half of 2027. Initial deals and trial launches are to be funded directly from the company's balance sheet. The company positions itself as a partner that can execute on what biotech and pharma companies have built, collaborating with them to "take medicines further, faster."

Lindus Health Limited is a London-based company operating in the clinical research and drug development sector. According to its own account, it was originally founded as a technology-first clinical research organisation (CRO). In that phase, the company focused on running clinical trials using technology to automate manual processes, recruit patients directly and provide real-time access to data, positioning itself as a faster, higher-quality alternative to traditional trial delivery. The company subsequently changed strategic direction. It now describes itself as strictly focused on in-licensing, co-developing and acquiring assets to advance using its trial delivery capability. This shift moved Lindus from a pure service provider model toward an asset-centric drug development model, while retaining the trial platform as its core execution advantage. Under its current strategy, Lindus in-licenses Phase I–III ready assets, concentrating on non-ultrarare chronic disease that aligns with its core therapeutic areas and proven execution capabilities. It uses proprietary data and AI models to identify assets that fit its operational capabilities and therapeutic expertise. The company then develops assets internally and assesses acquisition, partnering, later-stage development or commercialisation as the path forward. Lindus reports $80 million in total funding and a team of 80 people across the United States and Europe. It states that it has completed more than 45 Phase I–IV trials across broad therapeutic areas, and that 82% of its trials completed enrollment on or ahead of timeline, measured against all 28 trials that completed enrollment within the past three years where Lindus was responsible for enrollment. Its global trial execution spans the US, UK and Europe, with integrated Asia-Pacific partnerships. For its asset development pipeline, Lindus says it is targeting deal close on initial assets through 2026, with first trials launching in the first half of 2027. Initial deals and trial launches are to be funded directly from the company's balance sheet. The company collaborates with biotech and pharma partners, positioning itself as a partner that can execute on what those partners have built.

• Originally founded as a technology-first clinical research organisation (CRO).

• Repositioned to focus strictly on in-licensing, co-developing and acquiring assets to advance using its trial delivery capability.

• Reported $80 million in total funding and a team of 80 people across the US and Europe.

• Completed more than 45 Phase I–IV trials across broad therapeutic areas.

• Targeting deal close on initial in-licensed assets through 2026, with first trials launching in H1 2027.

A technology-first clinical trial and drug development partner that executes faster, higher-quality trials and advances in-licensed assets across the US, UK and Europe.

• Integrated clinical trial platform

  Technology-enabled platform that automates manual processes, recruits patients directly and provides real-time access to data.

• In-licensed Phase I–III asset development

  In-licensing, co-developing and acquiring Phase I–III ready assets in non-ultrarare chronic disease, developed internally and then assessed for acquisition, partnering, later-stage development or commercialisation.

• 2021-11-05

  Lindus Health announces $5 million seed funding[3]Lindus Health宣布获得500万美元种子轮融资finanznachrichten.de

  Reported: 2021-11-05

  Lindus Health announced a $5 million seed round, with investors including Firstminute Capital, Presight Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm Ventures. The funding was intended to scale the Lindus Health team.

• 2021-11-05

  Lindus Health launches[3]Lindus Health宣布获得500万美元种子轮融资finanznachrichten.de

  Reported: 2021-11-05

  Lindus Health publicly launched, offering a clinical-trial platform focused on helping healthcare companies conduct trials.

1. 1Lindus Therapeutics | Homelindushealth.com
2. 2Lindus Health Limited (United Kingdom) - Wikidatawikidata.org
3. 3Lindus Health宣布获得500万美元种子轮融资finanznachrichten.de